KEYMED BIOSCIENCES -0001 (64Z) — Net Asset Quality Index
KEYMED BIOSCIENCES -0001 (64Z) has a Net Asset Quality Index of 65.8% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €4.22 Billion minus total liabilities of €1.44 Billion yields net assets of €2.77 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See how many days can KEYMED BIOSCIENCES -0001 fund operations to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
KEYMED BIOSCIENCES -0001 Net Asset Quality Index Over Time (2021–2025)
This chart shows how KEYMED BIOSCIENCES -0001's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the index stands at 65.8%, representing net assets of €2.77 Billion against total assets of €4.22 Billion EUR. Explore 64Z cash flow metrics to assess how effectively this company generates cash.
Annual Net Asset Quality Index for KEYMED BIOSCIENCES -0001 (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for KEYMED BIOSCIENCES -0001 from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 64Z market cap overview.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 65.8% | €2.77 Billion | €4.22 Billion | €1.44 Billion | ▲ +0.1 pp |
| 2024 | 65.7% | €2.48 Billion | €3.77 Billion | €1.29 Billion | ▼ -11.2 pp |
| 2023 | 76.9% | €2.99 Billion | €3.88 Billion | €896.11 Million | ▼ -8.0 pp |
| 2022 | 84.9% | €3.34 Billion | €3.93 Billion | €593.10 Million | ▼ -7.7 pp |
| 2021 | 92.7% | €3.65 Billion | €3.93 Billion | €289.07 Million | — |